Diasome Pharmaceutical's poster presentation will be focusing on the administration of Oral HDV-Insulin in a food-dose timing trial. The following abstract will be presented as a poster from Saturday, June 6 through Monday, June 8 in the Morial Convention Center's Hall D and Hall E:
A Single-Blind, Placebo-Controlled, Food-Dose Timing Trial of Oral HDV-Insulin in Patients with Type 2 Diabetes Mellitus. Blair Geho, MD, PhD, John Lau, Len Rosenberg, PhD, RPh, Sherwyn Schwartz, MD. Diasome Pharmaceuticals, Conshohocken, PA and Diabetes Glandular Research Center, San Antonio, TX.
Diasome's Oral HDV-Insulin is a nanotechnology-based cell targeting system for the improved treatment of diabetes mellitus. This drug delivery system is specifically targeted to hepatocytes, the primary metabolic cells in the liver. Diasome's therapies have been tested in more than 250 subjects through Phase II studies, and have shown the ability to lower blood glucose levels in diabetics.